TY  - CHAP
M1  - Book, Section
TI  - Chapter 227. Cytotoxic and Antimetabolic Agents
A1  - High, Whitney A.
A1  - Fitzpatrick, James E.
A2  - Goldsmith, Lowell A.
A2  - Katz, Stephen I.
A2  - Gilchrest, Barbara A.
A2  - Paller, Amy S.
A2  - Leffell, David J.
A2  - Wolff, Klaus
PY  - 2012
T2  - Fitzpatrick's Dermatology in General Medicine, 8e
AB  - |PrintCytotoxic  and  Antimetabolic  Agents  at  a  GlanceCytotoxic  and  antimetabolic  agents  are  used  in  dermatology  to  treat  serious,  life-threatening,  and  recalcitrant  disease.Common  agents  used  in  dermatology  include  methotrexate,  azathioprine,  mycophenolate  mofetil,  thioguanine,  hydroxyurea,  cyclophosphamide,  chlorambucil,  and  liposomal  doxorubicin.Methotrexate  is  US  Food  and  Drug  Administration  (FDA)  approved  for  treatment  of  psoriasis  and  advanced  mycosis  fungoides,  whereas  cyclophosphamide  is  FDA  approved  for  advanced  mycosis  fungoides  only,  and  liposomal  doxorubicin  is  approved  for  acquired  immunodeficiency  syndrome-related  Kaposi  sarcoma;  other  uses  of  the  agent  in  this  chapter  occur  on  an  “off-label”  basis.Cytotoxic  and  antimetabolic  agents  act  through  inhibition  and/or  interruption  of  the  cell  cycle.Side  effects  and  complications  with  these  potentially  dangerous  medications  are  numerous,  and  close  clinical  follow-up  and  laboratory  evaluation  is  necessary.Cytotoxic  agents  used  in  dermatology,  as  well  as  those  initiated  for  other  purposes,  may  yield  distinctive  cutaneous  eruptions  and  cutaneous  sequelae.  
SN  - 
PB  - The McGraw-Hill Companies
CY  - New York, NY
Y2  - 2024/04/25
UR  - accessmedicine.mhmedical.com/content.aspx?aid=56099314
ER  -